IMMUNO-LUNG : Identification of Biomarkers and Therapeutic Targets for Pulmonary Immunotherapy

Recruiting now · Not applicable

Conditions studied: Non-small Cell Lung Cancer

In brief

Immunotherapy has helped improve the prognosis of metastatic lung cancer. However, only about 40% of patients respond to conventional immunotherapy with anti-PD(L)-1 agents. This research aims to identify biomarkers of response to immunotherapy at the tumor level and to characterize new therapeutic targets

Key facts

Study ID

NCT07608835

Run by

Institut Paoli-Calmettes

People needed

200

Starts

2026-02-12

Expected to finish

2033-05-12

Last updated by the study team

2026-05-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients aged 18 years or older, male or female.
• Willing to participate in the study and having signed a written informed consent form.
• Presenting a strong suspicion of localized resectable or advanced unresectable non-small cell lung cancer, or having a histologically confirmed non-small cell lung cancer.
• Affiliated with a social security system or benefiting from such a system.

You may not qualify if…

• Individuals in an emergency situation, adults under legal protection (guardianship, curatorship, or judicial protection), or individuals unable to provide informed consent.
• Inability to comply with the medical follow-up required by the study for geographical, social, or psychological reasons.
• History of solid organ transplantation or hematopoietic stem cell transplantation.
• Pregnant or breastfeeding women.

Where it is running

• Rochigneux — Marseille, Institut Paoli Calmettes, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.